AIDSInfo logo
Home > Clinical Guidelines > Perinatal Guidelines

Perinatal Guidelines

Related Content

Order PublicationSupplementsSlide SetsFact SheetsDrugs
How to CiteClinical Trials 
Manuals Back
Adapted from Perinatal Treatment Guidelines Table 3: Antiretroviral Drug Use in Pregnant HIV-Infected Women: Recomendations for Use in Pregnancy - Updated on April 29, 2009

Recommended Agents Recommended Agents
Lamivudine Lopinavir/ritonavir
Alternate Agents
Alternate Agents Atazanavir


Didanosine Nelfinavir
Emtricitabine Ritonavir
Stavudine Saquinavir [HGC]r/ritonavir
Use in Special Circumstances
Tenofovir Insufficient Data to Recommend
NNRTIs Fosamprenavir
Recommended Agents Tipranavir
Use in Special Circumstances
Efavirenz Entry Inhibitors
Insufficient Data to Recommend
Insufficient Data to Recommend Enfuvirtide
Etravirene Maraviroc
Integrase Inhibitor
Insufficient Data to Recommend

How to Cite the Perinatal Guidelines:
Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. April 29, 2009; pp 1-90. Available at Accessed (insert Date) [include page numbers, table number, etc. if applicable]
Clinical TrialsBack
29 studies were found.                 

RecruitingBlood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery
Condition: HIV Infections
En español
RecruitingAntiviral Responses to a Nevirapine-Based Regimen Versus a Lopinavir/Ritonavir-Based Regimen in HIV Infected Infants Who Have or Have Not Received Single Dose Nevirapine for the Prevention of Mother-to-Child Transmission of HIV
Condition: HIV Infections
En español
RecruitingReducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth
Condition: HIV Infections
En español
RecruitingComparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy
Condition: HIV Infections
En español
RecruitingPharmacokinetic Study of Anti-HIV Drugs During Pregnancy
Condition: HIV Infections
En español
RecruitingPrenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission
Condition: HIV Infections; Pregnancy Complications, Infectious
En español
RecruitingMaternal and Infant Peripartum Nevirapine, Versus Infant Only Peripartum Nevirapine, or Maternal Lopinavir/Ritonavir in Addition to Standard Zidovudine Prophylaxis for the Prevention of Perinatal HIV in Thailand
Condition: HIV Infections; Pregnancy
RecruitingStudy of DDT and Loss of Clinically-Recognized Pregnancies in South Africa
Condition: Spontaneous Abortion; Malaria; Pregnancy Outcome; Stillbirth; HIV
RecruitingHSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding
Condition: HIV Infections; Herpes Simplex
RecruitingPharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-Partum
Condition: HIV Infections
Not yet recruitingElizabeth Glaser Pediatric AIDS Foundation (EGPAF)Antiretroviral Pregnancy Registry A Multi-Site Protocol
Condition: HIV Infections; HIV Positive; Pregnant Women
Not yet recruitingEvaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy
Condition: Pregnancy; Malaria Prevention; HIV Infections
RecruitingPharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy
Condition: HIV Infections; Pregnancy
Not yet recruitingA Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With TMC114r (Ritonavir), and TMC125 (Etravirine) in HIV-1 Infected Pregnant Women
Condition: HIV Infections; Pregnancy; HIV
RecruitingEffectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women
Condition: Pregnancy; HIV Infections; Sexually Transmitted Diseases
RecruitingDaily Co-Trimoxazole Prophylaxis to Prevent Malaria in Pregnancy
Condition: Malaria in Pregnancy, With or Without HIV Infection
RecruitingThe Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet
Condition: Pregnancy; HIV
Not yet recruitingCommunity-Based Evaluation of a Pilot PMTCT Project in Kafue District
Condition: HIV-Free Survival; HIV Infections
Not yet recruitingRoutine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia
Condition: HIV Infections
RecruitingPrevention of Perinatal Sepsis (PoPS): Evaluation of Chlorhexidine Wipes of Birth Canal and Newborn
Condition: Infant, Newborn, Diseases; Sepsis; Puerperal Infection
Not yet recruitingReducing HIV Risk Among Pregnant Women in Drug Treatment
Condition: HIV Risk Behavior
RecruitingPharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women
Condition: HIV Infections
RecruitingNevirapine Clearance After Short-Term Highly Active Antiretroviral Therapy (HAART) for Prevention of Mother to Child Transmission of HIV (PMTCT)
Condition: NVP Plasma Level; NVP Related Mutation; 3TC Related Mutation
RecruitingDevelopment of Resistance Mutations in Pregnant HIV-Positive (+) Women Following Perinatal Antiretroviral Therapy in Israel
Condition: HIV Infections
RecruitingMulti-Level Interventions for STD Prevention Among Adolescents
Condition: Chlamydia
RecruitingMulti-Sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.
Condition: HIV Infections; Hepatitis B Virus
RecruitingContinuous Use of COCs
Condition: Pregnancy Prevention
RecruitingAntiretroviral Drug Levels During and After Pregnancy
Condition: Pharmacokinetics
RecruitingPharmacokinetics of Antiretroviral Agents in HIV-Infected Pregnant Women.
Condition: HIV Infections
Important Notice:
This document has been submitted for publication to CDC's Morbidity and Mortality Weekly Report (MMWR) and should be considered a final draft. It is being posted on AIDSinfo to expedite dissemination of important clinical information. Upon acceptance and publication in MMWR, this draft will be removed and replaced by the published version. In the meantime, readers should be aware that the content of the draft might differ from the content of future published versions. Any corrections/questions concerning this document should be addressed to Ms. Jessica Carrington (e-mail:
Close window